ECB-ART-50144
Gen Thorac Cardiovasc Surg
2011 Aug 01;598:527-37. doi: 10.1007/s11748-010-0743-3.
Show Gene links
Show Anatomy links
Molecular oncology of lung cancer.
Toyooka S
,
Mitsudomi T
,
Soh J
,
Aokage K
,
Yamane M
,
Oto T
,
Kiura K
,
Miyoshi S
.
???displayArticle.abstract???
Progress in genetic engineering has made it possible to elucidate the molecular biological abnormalities in lung cancer. Mutations in KRAS and P53 genes, loss of specific alleles, and DNA methylation of the tumor suppressor genes were the major abnormalities investigated between 1980 and the 2000s. In 2004, mutations in the epidermal growth factor receptor (EGFR) gene that cause oncogene addiction were discovered in non-small-cell lung cancers (NSCLCs), especially in adenocarcinomas. Because they are strongly associated with sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs), a great deal of knowledge has been acquired in regard to both EGFR and other genes in the EGFR family and their downstream genes. Moreover, in 2007 the existence of the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene was discovered in NSCLC; and the same as EGFR-TKIs, ALK inhibitors are being found to be highly effective in lung cancers that have this translocation. These discoveries graphically illustrate that molecular biological findings are directly linked to the development of clinical oncology and to improving the survival rates of lung cancer patients. Here, we review the remarkable progress in molecular biological knowledge acquired thus far in regard to lung cancer, especially NSCLC, and the future possibilities.
???displayArticle.pubmedLink??? 21850578
???displayArticle.link??? Gen Thorac Cardiovasc Surg
References [+] :
Albanell,
High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage.
1997, Pubmed
Albanell, High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. 1997, Pubmed
Bader, Oncogenic PI3K deregulates transcription and translation. 2005, Pubmed
Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function. 2004, Pubmed
Belinsky, Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. 1998, Pubmed
Burbee, Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. 2001, Pubmed
Cappuzzo, Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. 2004, Pubmed
Cappuzzo, Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. 2005, Pubmed
Cappuzzo, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. 2005, Pubmed
Colby, Precursors to pulmonary neoplasia. 1998, Pubmed
Daly, A homozygous deletion on chromosome 3 in a small cell lung cancer cell line correlates with a region of tumor suppressor activity. 1993, Pubmed
Dammann, Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. 2000, Pubmed
Davis, Transcriptional regulation by MAP kinases. 1995, Pubmed
Engelman, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. 2007, Pubmed
Ewen, The cell cycle and the retinoblastoma protein family. 1994, Pubmed
Eymin, Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. 2002, Pubmed
Fearon, A genetic model for colorectal tumorigenesis. 1990, Pubmed
Fontanini, Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. 1997, Pubmed
Fukui, Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. 2008, Pubmed
Gandhi, Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. 2009, Pubmed
Garzon, MicroRNAs in Cancer. 2009, Pubmed
Girard, Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. 2000, Pubmed
Greider, The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. 1987, Pubmed
Gridelli, The potential role of mTOR inhibitors in non-small cell lung cancer. 2008, Pubmed
Guo, Relationship between matrix metalloproteinase 2 and lung cancer progression. 2007, Pubmed
Hainaut, Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. 2001, Pubmed
Harris, p53 tumor suppressor gene: from the basic research laboratory to the clinic--an abridged historical perspective. 1996, Pubmed
Hayashita, A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. 2005, Pubmed
Hiyama, Telomerase activity in small-cell and non-small-cell lung cancers. 1995, Pubmed
Ichihara, The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. 2007, Pubmed
Inamura, EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. 2009, Pubmed , Echinobase
Inukai, Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. 2006, Pubmed
Jackman, Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. 2009, Pubmed
Jemal, Cancer statistics, 2009. 2009, Pubmed
Jida, Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment. 2009, Pubmed
Kalluri, The basics of epithelial-mesenchymal transition. 2009, Pubmed
Kim, Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. 2008, Pubmed
Knudson, Mutation and cancer: statistical study of retinoblastoma. 1971, Pubmed
Kobayashi, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. 2005, Pubmed
Kubo, MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. 2009, Pubmed
Kubo, DNA methylation in small lung adenocarcinoma with bronchioloalveolar carcinoma components. 2009, Pubmed
Kumar-Sinha, Recurrent gene fusions in prostate cancer. 2008, Pubmed
Lemjabbar-Alaoui, Wnt and Hedgehog are critical mediators of cigarette smoke-induced lung cancer. 2006, Pubmed
Leung, Vascular endothelial growth factor is a secreted angiogenic mitogen. 1989, Pubmed
Lynch, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. 2004, Pubmed
Marks, Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. 2008, Pubmed
McDermott, Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. 2008, Pubmed
Mitsudomi, Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. 1991, Pubmed
Mitsudomi, p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. 1992, Pubmed
Onozato, Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. 2009, Pubmed
Ozes, NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. 1999, Pubmed
Paez, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. 2004, Pubmed
Pal, The role of targeting mammalian target of rapamycin in lung cancer. 2008, Pubmed
Pao, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. 2005, Pubmed
Patel, ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. 2008, Pubmed
Pulford, Anaplastic lymphoma kinase proteins in growth control and cancer. 2004, Pubmed
Raponi, MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. 2009, Pubmed
Roche, Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. 1996, Pubmed
Rohr, Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer. 2005, Pubmed
Sandler, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. 2006, Pubmed
Serrano, Role of the INK4a locus in tumor suppression and cell mortality. 1996, Pubmed
Sharma, Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock". 2010, Pubmed
Sharma, A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. 2006, Pubmed
Shaw, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. 2009, Pubmed
Sherr, Cancer cell cycles. 1996, Pubmed
Shigematsu, Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. 2006, Pubmed
Shigematsu, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. 2005, Pubmed
Soda, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. 2007, Pubmed , Echinobase
Soh, Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer. 2007, Pubmed
Soh, Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. 2009, Pubmed
Sozzi, The FHIT gene 3p14.2 is abnormal in lung cancer. 1996, Pubmed
Sullivan, Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. 2010, Pubmed
Takahashi, p53: a frequent target for genetic abnormalities in lung cancer. 1989, Pubmed
Takamizawa, Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. 2004, Pubmed
Takeuchi, KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. 2009, Pubmed
Tang, EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. 2005, Pubmed
Toyooka, DNA methylation profiles of lung tumors. 2001, Pubmed
Toyooka, Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. 2006, Pubmed
Tsuchida, Nucleotide sequence of the oncogene encoding the p21 transforming protein of Kirsten murine sarcoma virus. 1982, Pubmed
Turke, Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. 2010, Pubmed
VanderBorght, Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells. 2006, Pubmed
Vivanco, The phosphatidylinositol 3-Kinase AKT pathway in human cancer. 2002, Pubmed
Watkins, Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. 2003, Pubmed
Weinstein, Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. 2006, Pubmed
Weir, Characterizing the cancer genome in lung adenocarcinoma. 2007, Pubmed
Westhoff, Alterations of the Notch pathway in lung cancer. 2009, Pubmed
Wistuba, Molecular genetics of small cell lung carcinoma. 2001, Pubmed
Yamamoto, PIK3CA mutations and copy number gains in human lung cancers. 2008, Pubmed
Yanaihara, Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. 2006, Pubmed
Yano, Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. 2008, Pubmed
Yarden, The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. 2001, Pubmed
Yatabe, EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. 2005, Pubmed
Zhang, ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. 1998, Pubmed
Zöchbauer-Müller, 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. 2001, Pubmed